Actively Recruiting
Phase 2 Evaluation of MZE829 Capsules for Safety and Albuminuria Effects in Adults with Proteinuric Chronic Kidney Disease and APOL1 High Risk Genotype
Led by Maze Therapeutics · Updated on 2026-07-27
74
Participants Needed
79
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This trial investigates MZE829 capsules in adults with proteinuric chronic kidney disease who also carry the APOL1 high risk genotype, specifically G1G1, G2G2, or G1G2 variants. The study aims to evaluate the safety, tolerability, and impact on albuminuria, a marker of kidney damage, in this population. It is an open-label Phase 2 trial, meaning all participants receive the study drug and results will help determine its effects and safety profile. Participants receive MZE829 capsules orally in a single-group design. The study includes two cohorts one with chronic kidney disease alongside diabetes, and another with chronic kidney disease without diabetes. The treatment and monitoring occur over a 12-week period, during which the study team assesses drug safety and effects on albuminuria levels. During the trial, participants will be monitored for adverse events and tolerability from baseline through week 12. Researchers will also measure changes in urine albumin-to-creatinine ratio UACR to evaluate kidney function. Blood samples will be taken to assess plasma drug concentrations. The total participation time is approximately 12 weeks, focusing on safety and biological effects of MZE829.
CONDITIONS
Brief Title
A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
Research Team
M
Maze Therapeutics
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here